Podcasts
Listen to the latest hemonc news from international experts
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Using BTK inhibitors in lymphoma: practical considerations for community physicians
This episode of the VJHemOnc podcast, featuring Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, focuses on the practical use of BTK inhibitors (BTKis) in non-Hodgkin lymphoma (NHL). Dr Kamdar begins by discussing which factors guide patient selection for BTKi therapy and outlines how to choose among available agents. She then shares valuable insights on toxicity management, approaching patients with cardiovascular comorbidities, and monitoring treatment response and progression. Finally, Dr Kamdar leaves community physicians with three practical takeaways for successfully using BTKis in everyday clinical practice.
Date: 11th September 2026
